B+
Bull case
20%
Probability
Target price
$0.25
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
VVOS
Vivos TherapeuticsFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.12
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.04
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-29
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+37.0
Score
AI commentary
Sparse headlines highlight Q2 growth, but SEC disclosures make liquidity, dilution and listing compliance more decision-relevant. No dependable post-print analyst revisions or verified release-linked price reaction were supplied. Zero sentiment and positioning fields denote unavailable inputs, not neutral readings.
RankAlpha Sentiment Codex - 2026-09-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-14eventNasdaq compliance and financing decisionsHigh impact
Vivos disclosed stockholders' equity and minimum-bid deficiencies. Its filing described October 14 as a possible equity-compliance extension deadline if Nasdaq accepted its plan—not a confirmed cure. Financing terms and listing decisions remain material. [#10-Q-2026-08-14] https://www.sec.gov/Archives/edgar/data/1716166/000149315226038336/form10-q.htm
2026-12-31catalystDebt exchange creates a substantial share-supply overhangHigh impact
An August 31 agreement permits exchange of $2.86 million of secured-note principal for up to 11.45 million common shares. Debt reduction helps, but issuance and selling could materially dilute holders. [#8-K-2026-09-08] https://www.sec.gov/Archives/edgar/data/1716166/000149315226041616/form8-k.htm
2027-06-30catalystSleep-center service growth must improve cash conversionHigh impact
Q2 revenue rose 35% to about $5.2 million, led by sleep-testing and treatment services, while gross margin reached 57%. Yet first-half operating cash use was $9.2 million and June cash was $1.8 million. Sustained service growth with lower burn would strengthen the case; another cash shortfall would weaken it. [#10-Q-2026-08-14] https://www.sec.gov/Archives/edgar/data/1716166/000149315226038336/form10-q.htm
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-29 • Updated nightlySource: Internal modelMethodology